 recurr metastat head neck squamou cell carcinoma clinic univari multivari analysi respons surviv cisplatin-bas chemotherapi patient recurr and/or metastat head neck squamou cell cancer consecut phase II trial cisplatinum c-ddp combin c-ddp bleomycin fluorouracil cfb patient cisplatinum vindesin patient CV cfb combin c-ddp continu infus hour patient day patient CV regimen differ schedul vd weekli patient continu infus patient follow variabl sex age perform statu previou therapi local recurr length disease-fre interv dfi distant metastas weight loss primari site histolog differenti type chemotherapi previou chemotherapi evaluable/measur diseas erythrosediment rate relat respons chemotherapi who surviv univari multivari analysi cox overal respons rate RR CR PR cfb protocol RR NS CV combin group differ combin RR cfb c-ddpci cfb c-ddp hour CV vd CV vdsci patient popul differ combin metastat patient univari analysi multipl variabl age year previou therapi absenc local relaps metastat diseas dfi measur diseas signific probabl respons median surviv month patient month nonrespond month respond univari analysi signific factor surviv weight loss long dfi respons erythrosediment rate esr hr presenc bone metastasi number metastas multivari analysi show PS absenc local relaps disease-fre interv signific prognost factor respons multivari analysi factor signific surviv PS weight loss respons analysi clinic pattern evolut RR local recurr diseas untreat patient metastat diseas present abstract truncat AT word